Prenylation inhibitors reduce host cell permissiveness to viral replication
View Patent ↗Permissiveness of human cells to replication of susceptible pathogenic human viruses is reduced by treating the cells with a selective inhibitor of prenylation of a host cell protein. Target viruses, especially Flaviviridae, are predetermined to lack a CXXX box and prenylated viral protein, and to be replication-dependent on host protein prenylation. The general method comprises (a) contacting human cells subject to infection by the virus with an effective amount of a selective inhibitor of a prenylation enzyme of the cells; and (b) confirming a resultant reduction in permissiveness of the cells to replication of the virus. Targeted enzymes include prenyl biosynthetic enzyme like HMG CoA reductase farnesyl and/or geranylgeranyl transferase enzymes.
1. A method for reducing permissiveness of human cells to replication of a human pathogenic Flaviviridae virus predetermined (I) to lack any C-terminal CXXX box; (ii) to lack prenylated viral protein, and (iii) to be replication-dependent on host protein prenylation, the method comprising steps:
(a) contacting human cells subject to infection by the virus with an effective amount of a selective inhibitor of a prenylation enzyme of the cells, wherein the enzyme is selected from the group consisting of an HMG CoA reductase and a prenyltransferase; and
(b) confirming a resultant reduction in permissiveness of the cells to replication of the virus.
2. The method of claim 1 , wherein the enzyme is HMG CoA reductase.
3. The method of claim 1 , wherein the enzyme is HMG CoA reductase and the inhibitor is selected from the group consisting of: atorvastatin (Lipitor), pravastatin (Pravachol), lovastatin (Mevacor), simvastatin (Zocor), fluvastatin (Lescol) and rosuvastatin calcium (Crestor).
4. The method of claim 1 , wherein the enzyme is geranylgeranyl transferase I (GGTase I).
5. The method of claim 1 , wherein the enzyme is geranylgeranyl transferase I (GGTase I), and the inhibitor is selected from the group consisting of: GGTI-286, GGTI-298, Massadine, and a Candida albicans GGTase I inhibitor.
6. The method of claim 1 , wherein the virus is a hepatitis C virus (HCV).
7. The method of claim 2 , wherein the virus is a hepatitis C virus (HCV).
8. The method of claim 3 , wherein the virus is a hepatitis C virus (HCV).
9. The method of claim 4 , wherein the virus is a hepatitis C virus (HCV).
10. The method of claim 5 , wherein the virus is a hepatitis C virus (HCV).
11. The method of claim 1 , wherein the virus is a West Nile virus (WNV).
12. The method of claim 2 , wherein the virus is a West Nile virus (WNV).
13. The method of claim 3 , wherein the virus is a West Nile virus (WNV).
14. The method of claim 4 , wherein the virus is a West Nile virus (WNV).
15. The method of claim 5 , wherein the virus is a West Nile virus (WNV).